News

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.

The European Medicines Agency (EMA) granted orphan designation to Emerald Health Pharmaceuticals’ (EHP) EHP-102 for the treatment of Huntington’s disease. Orphan status is given to medications designed to treat, prevent or diagnose rare life-threatening or chronically debilitating disorders that affect no more than five…

Rexulti (brexpiprazole), an antipsychotic medicine approved for schizophrenia and in some cases depression, eases motor and psychiatric symptoms of Huntington’s disease, according to a case study. The study, “Effectiveness of Brexpiprazole in the Treatment in a Patient with Huntington’s Disease,” was published in the…

Railway signalman Sandy Patience has witnessed the devastating effects of Huntington’s disease on family members. When he learned two years ago that he, too, inherited the neurodegenerative disorder, the news was crushing. But now, as one of the first Scotland residents to participate in an international Phase 3 trial…

As many as 80 experts from a dozen countries will gather next month in Vienna for the European Conference on Controversies in Huntington’s Disease (ECCH2020). The Feb. 13–14 meeting “aims to increase awareness and interests around the main aspects” of Huntington’s disease, which according to the European…